Pfizer completed its $67 billion acquisition of one-time-competitor Wyeth Pharmaceuticals on October 15, just one in a string of recent mergers and acquisitions in the pharmaceutical industry. (Think Merck’s November 3 merger with Schering-Plough and Genentech’s March 26 deal with Roche.) According to a variety of sources, plans are already in place to merge the companies’ meetings teams, but Pfizer representatives are staying very close-lipped about the process, and so far, there are more ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only unlock the Pfizer-Wyeth Merger Rolls Forward; Meetings Casualties Still Uncertain, you'll also gain access to exclusive premium content.

Already registered? here.